Physician profile
Asma Khan
NPI 1922363175
$556.47
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $185 · 2021: $45.75 · 2022: $27.61.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $125.28 | 2019-2020 | |
| Allergan, INC. | $90.97 | 2019-2020 | |
| Abbvie INC. | $73.36 | 2021-2022 | |
| Glaxosmithkline, LLC. | $54.79 | 2019-2020 | |
| Amarin Pharma, INC. | $53.03 | 2020 | |
| Pfizer INC. | $51.18 | 2019-2020 | |
| Astellas Pharma US INC | $28.79 | 2019-2020 | |
| Amgen INC. | $15.77 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.62 | 2019 | |
| Merck Sharp & Dohme LLC | $13.45 | 2019 | |
| Vanda Pharmaceuticals INC. | $11.94 | 2020 | |
| Lilly USA, LLC | $11.79 | 2020 | |
| Sunovion Pharmaceuticals INC. | $11.50 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asma Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.